Literature DB >> 3045818

Immunoregulatory activities of human immunodeficiency virus (HIV) proteins: effect of HIV recombinant and synthetic peptides on immunoglobulin synthesis and proliferative responses by normal lymphocytes.

M P Nair1, R Pottathil, E P Heimer, S A Schwartz.   

Abstract

Recombinant and synthetic peptides corresponding to envelope proteins of the human immunodeficiency virus (HIV) were examined for their effects on the activities of lymphocytes from normal donors in vitro. Although lymphocytes cultured with env-gag peptides produced significant amounts of IgG, addition of env-gag peptides to a pokeweed mitogen-induced B-cell activation system resulted in suppression of immunoglobulin synthesis by normal lymphocytes. Recombinant antigens, env-gag and env-80 dihydrofolate reductase (DHFR), produced a substantial proliferative response by peripheral blood mononuclear cells (PBMC) as determined by [3H]thymidine incorporation. PBMC precultured with HIV synthetic peptide env 578-608 also manifested significant proliferative responses as compared to control cultures. CD3+ lymphocytes precultured with recombinant HIV antigens, env-gag and env-80 DHFR, and synthetic HIV peptide, env 487-511, showed moderate but significant proliferative responses. Both recombinant antigens and synthetic peptides also produced a dose-dependent stimulatory effect on proliferation by CD3- lymphocytes. Stimulation of CD3+ and CD3- lymphocyte subpopulations induced by env-gag peptides was specifically inhibited by goat anti-env-gag polyclonal antibodies, demonstrating the specificity of the reaction. These studies demonstrate that recombinant and synthetic peptides of the HIV genome express immunoregulatory T- and B-cell epitopes. Identification of unique HIV epitopes with immunogenic and immunoregulatory activities is necessary for the development of an effective vaccine against HIV infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3045818      PMCID: PMC282000          DOI: 10.1073/pnas.85.17.6498

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

Review 1.  Intrinsic and extrinsic factors in protein antigenic structure.

Authors:  J A Berzofsky
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

2.  Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.

Authors:  B H Hahn; M A Gonda; G M Shaw; M Popovic; J A Hoxie; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

3.  Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.

Authors:  K Krohn; W G Robey; S Putney; L Arthur; P Nara; P Fischinger; R C Gallo; F Wong-Staal; A Ranki
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 4.  The antigenic structure of proteins: a reappraisal.

Authors:  D C Benjamin; J A Berzofsky; I J East; F R Gurd; C Hannum; S J Leach; E Margoliash; J G Michael; A Miller; E M Prager
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

5.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

6.  HTLV-III env gene products synthesized in E. coli are recognized by antibodies present in the sera of AIDS patients.

Authors:  R Crowl; K Ganguly; M Gordon; R Conroy; M Schaber; R Kramer; G Shaw; F Wong-Staal; E P Reddy
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

7.  HTLV-III infection in brains of children and adults with AIDS encephalopathy.

Authors:  G M Shaw; M E Harper; B H Hahn; L G Epstein; D C Gajdusek; R W Price; B A Navia; C K Petito; C J O'Hara; J E Groopman
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

8.  Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus.

Authors:  M A Gonda; F Wong-Staal; R C Gallo; J E Clements; O Narayan; R V Gilden
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

9.  Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines.

Authors:  L Montagnier; J Gruest; S Chamaret; C Dauguet; C Axler; D Guétard; M T Nugeyre; F Barré-Sinoussi; J C Chermann; J B Brunet
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

10.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

View more
  17 in total

Review 1.  In vitro and animal models of human immunodeficiency virus infection of the central nervous system.

Authors:  Chadd E Nesbit; Stanley A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 2.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

3.  Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes.

Authors:  Nimisha Gandhi; Zainulabedin Saiyed; Samikkannu Thangavel; Jose Rodriguez; K V K Rao; Madhavan P N Nair
Journal:  AIDS Res Hum Retroviruses       Date:  2009-07       Impact factor: 2.205

4.  Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2.

Authors:  M P Nair; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

5.  Synthetic peptides define the fine specificity of the human immunodeficiency virus (HIV) gp160 humoral immune response in HIV type 1-infected chimpanzees.

Authors:  R Q Warren; H Wolf; K R Shuler; J W Eichberg; R A Zajac; R N Boswell; P Kanda; R C Kennedy
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

6.  First documented case of human immunodeficiency virus type 2 infection in an asymptomatic Swiss subject.

Authors:  P Bürgisser; L Odier; J Schüpbach; P C Frei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

7.  Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis.

Authors:  S Sabbaj; M F Para; R J Fass; P W Adams; C G Orosz; C C Whitacre
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

8.  Relationship between IL-2 receptor expression and proliferative responses in lymphocytes from HIV-1 seropositive homosexual men.

Authors:  R K Chopra; N B Raj; J P Scally; A D Donnenberg; W H Adler; A J Saah; J B Margolick
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

9.  Human immunodeficiency virus type 1 envelope glycoproteins gp120 and gp160 induce interleukin-6 production in CD4+ T-cell clones.

Authors:  N Oyaizu; N Chirmule; Y Ohnishi; V S Kalyanaraman; S Pahwa
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

10.  Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals.

Authors:  Ellen R Van Gulck; Guido Vanham; Leo Heyndrickx; Sandra Coppens; Katleen Vereecken; Derek Atkinson; Eric Florence; Ilse Kint; Zwi Nisan Berneman; Viggo Van Tendeloo
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.